NASDAQ:ARMO ARMO BioSciences (ARMO) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free ARMO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$49.98▼$49.9850-Day Range$49.98▼$49.9852-Week Range$25.10▼$57.19VolumeN/AAverage Volume201,363 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ARMO BioSciences alerts: Email Address Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About ARMO BioSciences Stock (NASDAQ:ARMO)ARMO BioSciences, Inc., an immuno-oncology company, develops a pipeline of novel product candidates that activate the immune system of cancer patients to recognize and eradicate tumors in the United States. Its lead product candidate is AM0010, a long acting form of human interleukin-10 that is in Phase III randomized pivotal clinical trial for the treatment of pancreatic ductal adenocarcinoma. The company is also developing AM0010 that has completed Phase I/Ib clinical trial for the treatment of non-small cell lung cancer, renal cell carcinoma, colorectal cancer, and melanoma and breast cancer. In addition, it is developing AM0001, a monoclonal antibody against programmed cell death protein-1 checkpoint inhibitor; AM0015, a recombinant human interleukin-15; AM0012, a recombinant human Interleukin-12; and AM0003, a monoclonal antibody against leukocyte activating gene-3 protein program. The company was formerly known as Targenics, Inc. and changed its name to ARMO BioSciences, Inc. in December 2012. ARMO BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Read More Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now ARMO Stock News HeadlinesFebruary 3, 2024 | morningstar.comPacific Biosciences of California IncDecember 1, 2023 | msn.comPedro Pascal Gets Realistic Fantastic Four Armor As Reed Richards In Stunning MCU ArtMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…November 6, 2023 | finance.yahoo.comCaribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory BoardOctober 14, 2023 | msn.com5 Sizzling Well-Known Stocks Under $10 With Giant Upside PotentialJuly 21, 2023 | forbes.comArmor Protective PackagingMay 28, 2023 | msn.comBest Armor Sets In V Rising, RankedMay 11, 2023 | investing.comCodiak BioSciences Inc (CDAKQ)March 28, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. February 18, 2023 | msn.comPedro Pascal Has A Candid Confession About The Mandalorian ArmorFebruary 15, 2023 | msn.comPedro Pascal's Mandalorian Suit Is Way Clumsier To Wear In Real-Life Than On TVFebruary 14, 2023 | msn.comPedro Pascal Gets Asked About What It's Like To Wear The Mandalorian Armor And Gave A Very Honest ResponseJanuary 22, 2023 | finance.yahoo.comNovadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical OfficerJanuary 12, 2023 | finance.yahoo.comBoehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer ImmunotherapiesJanuary 2, 2023 | msn.comHow To Find All Wraith Lairs In Immortals Fenyx RisingDecember 14, 2022 | marketwatch.comMyocarditis Treatment Market Growth Share 2023 | Research by Future Prospects, Opportunities and Challenges, Key Dynamics and Size Forecast to 2028August 19, 2022 | chron.comTexas company hopes to 'de-extinct' Tasmanian tiger in next 10 yearsAugust 18, 2022 | nz.finance.yahoo.comHR Acuity Named to Inc. 5000 Annual ListAugust 13, 2022 | reuters.comEli Lilly and CoAugust 8, 2022 | businessinsider.com9 top West Coast biotechs that VCs say are poised to take off in the next yearAugust 2, 2022 | entrepreneur.com2 Stocks That Could Be Long-Term Winners for InvestorsJuly 19, 2022 | finance.yahoo.comInsilico Medicine Appoints Sujata Rao, M.D., as Senior Vice President to Oversee Clinical DevelopmentJuly 14, 2022 | msn.comHow to craft Hollowfang Battlegear in V RisingJuly 11, 2022 | msn.comHow To Farm Pristine Hide In V RisingJuly 8, 2022 | msn.comMetal Gear Rising: Revengeance - How To Beat GRADJuly 6, 2022 | msn.comHow to use console commands in V RisingJuly 4, 2022 | msn.comRising of the Shield Hero Season 2's Finale Is a Disappointing EndSee More Headlines Receive ARMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARMO BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/02/2018Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ARMO CUSIPN/A CIK1693664 Webwww.armobio.com Phone650-779-5075FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Peter Van Vlasselaer (Age 59)Founder, Pres, CEO & Director Mr. Herbert C. Cross (Age 46)Chief Financial Officer Dr. Joseph Leveque (Age 57)Chief Medical Officer Dr. Martin Oft (Age 51)Founder and VP of Pre-Clinical & Clinical Devel. Dr. Russell T. Kawahata (Age 64)VP of Technical Operations Key CompetitorsGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPPharvarisNASDAQ:PHVSView All Competitors ARMO Stock Analysis - Frequently Asked Questions How were ARMO BioSciences' earnings last quarter? ARMO BioSciences, Inc. (NASDAQ:ARMO) posted its quarterly earnings data on Monday, April, 2nd. The company reported ($9.62) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $9.17. What other stocks do shareholders of ARMO BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other ARMO BioSciences investors own include Standex International (SXI), Exelixis (EXEL), Tesla (TSLA), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Bausch Health Companies (BHC), EyePoint Pharmaceuticals (EYPT), Madrigal Pharmaceuticals (MDGL) and Progenics Pharmaceuticals (PGNX). When did ARMO BioSciences IPO? ARMO BioSciences (ARMO) raised $100 million in an initial public offering (IPO) on Friday, January 26th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Baird was co-manager. This page (NASDAQ:ARMO) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARMO BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.